Author: admin

Phictly Debuts New Social Club App and Platform for Lovers of Books, Films, and Culture

Designed to bring together fans of specific titles, Phictly shines a spotlight on each story for the best book club experience

DUNKIRK, Md. – May 7, 2025 – Phictly, an app and platform for book, film, and culture-lovers, today announced that it is launching a Kickstarter campaign to fund the completion of its technology. Phictly came into existence based on the experiences of its founders, who shared a common love of storytelling and a desire to create clubs based on one book, movie, or TV show.

Phictly founders tapped into their creative efforts, designing a platform that facilitates a more engaging online book club experience. “Our premise is that people want to gather online to discuss a particular title that they are excited about right now,” explained Nyleena Aiken, co-founder of Phictly. “We thought, ‘Perhaps we are not alone in joining a book club and finding that it has been ghosted or is no longer true to its original topic of interest?’ That was the birth of Phictly. We are at the threshold of an exciting new chapter where people connect through stories, the stories they love, and create a quality community.”

Phictly also promises to fill a gap in many people’s online lives. Aiken added, “Today’s fast-paced world makes it challenging to find genuine connections with people who love the same things. Books, films, and the emotions they evoke, bring us together in ways nothing else can.”

When people plan to dive into their next book or movie, the Phictly platform helps them create a club based on that single title, transforming their love for stories into an engaging, social experience. As users log into Phictly, they choose a book, movie, or show. Next, they select the pace or timeline for the club. Then, they select preferences and tags, finally inviting friends or other Phictly users to join in on the fun.

“No more ghosted discussions, unfocused themes, or oversized clubs where your voice gets lost,” said Aiken. “Say goodbye to burnout and boredom. We chose Kickstarter because it is an innovative destination hub, where people interested in everything new and unique look for products that meet their needs.”

To learn more, visit https://www.kickstarter.com/projects/phictly/phictly-your-pick-every-time-book-movie-and-tv-club-app

or Phictly.com

Media Contact
Company Name: Phictly
Contact Person: Media Relations
Email: Send Email
Country: United States
Website: https://Phictly.com

Retirement Planning Melbourne: Forward Path Advisory Dissects Federal Budget 2025, Analyses the Effects of Proposed Changes to Personal Finances

Retirement Planning Melbourne: Forward Path Advisory Dissects Federal Budget 2025, Analyses the Effects of Proposed Changes to Personal Finances
New tax reforms and superannuation adjustments in the Federal Budget 2025 could reshape retirement planning strategies, warns Forward Path Advisory’s financial experts.

As the Federal Budget 2025 looms, Australians are bracing for potential tax reforms, cost-of-living adjustments, and policy shifts that could significantly impact retirement planning in Melbourne, leaving those who fail to adapt unprepared for the evolving financial landscape.

The 2025 Federal Budget focuses on inflation relief, housing affordability, and economic growth. To avoid stoking inflation, it balances short-term relief with long-term reforms while prioritising cost-of-living support. The budget demands greater scrutiny as it is set to introduce sweeping adjustments to superannuation, tax brackets, and social security.

Top financial advisors in Melbourne are closely scrutinising the proposals, providing expert insights into what these changes mean for households and retirees. Among them, Radz Je CFP, Principal Financial Advisor at Forward Path Advisory, warns that specific proposals within the budget could reshape retirement plans for middle-income earners and believes proactive strategies are key to mitigating financial risks.

As a leading firm in retirement planning Melbourne clients rely on, Forward Path Advisory distinguishes itself through personalised, data-driven advice. Unlike generic financial planners, Radz Je and his team specialise in translating complex policy changes into actionable steps.

According to Radz Je, retirees may need to reassess their investment portfolios to maximise tax efficiency. The proposed changes to superannuation contribution caps and pension eligibility criteria could alter long-term savings strategies.

With inflation still a concern, the budget includes targeted tax relief and cost-of-living measures for low and middle-income earners. However, Forward Path Advisory cautions that not all households will benefit equally, urging individuals to seek tailored advice.

As these policy shifts take shape, potential adjustments to capital gains tax and negative gearing rules could influence property and share market investments. This underscores the importance of implementing adaptable, proactive retirement planning strategies to navigate these changes effectively.

With over 27 years of combined experience, Radz Je, fellow principal advisor Joel Cleary CFP, and their financial advisors offer expert guidance tailored to individuals seeking clarity amid the reforms.

For more information, visit https://www.forwardpathadvisory.com.au/

Experts at Forward Path Advisory believe it is never too early to start planning for retirement, and it encompasses several key areas to ensure a secure and fulfilling post-work life. Forward Path Advisory begins by defining the client’s retirement goals and aspirations before crafting a plan for their desired lifestyle.

Income stream planning is important, and maximising superannuation contributions and investment choices helps to build a robust retirement fund. At Forward Path Advisory, experienced financial advisors help to create and oversee an investment portfolio that aligns with the client’s risk tolerance and long-term financial security objectives.

“Our comprehensive retirement planning services focus on optimising your superannuation, effectively managing your savings, and establishing reliable income streams to support your needs. We help you plan for unexpected expenses, such as healthcare or home improvements, ensuring you’re well-prepared for any eventuality. With our tax-efficient strategies, we also minimise tax liabilities on retirement income and preserve the retiree’s accrued wealth,” said Radz Je.

Beyond income and tax planning, Forward Path Advisory offers estate planning services to help retirees establish a plan for asset distribution to beneficiaries, ensuring their wishes are honoured while minimising potential legal complications.

A trusted authority among financial advisors in Melbourne, the firm ensures clients remain ahead of regulatory shifts, cementing its reputation as professionals with extensive expertise in superannuation, tax optimisation, and wealth preservation.

About the Company:

Headquartered in Melbourne, Forward Path Advisory is a trusted financial planning firm specialising in retirement planning. Led by Principal Financial Advisor Radz Je, the firm provides tailored strategies for superannuation, tax efficiency, and wealth preservation. With a focus on clarity and education, Forward Path Advisory helps clients navigate complex financial landscapes, including Federal Budget changes and market shifts. Distinguished among Melbourne financial advisors, the firm combines data-driven insights with personalised service to secure long-term stability. Whether preparing for retirement or optimising investments, clients benefit from expert guidance and proactive planning.

Disclaimer: This press release may contain statements that project future plans and prospects, which are based on current expectations and are subject to risks and uncertainties. Actual results may differ.

Media Contact
Company Name: Forward Path Advisory
Contact Person: Radz Je
Email: Send Email
Address:Level 3/2 Brandon Park Dr
City: Wheelers Hill
State: VIC 3150
Country: Australia
Website: https://www.forwardpathadvisory.com.au/

Multiple Myeloma Market Set to Grow Substantially Through 2034, DelveInsight Projects | Johnson & Johnson Innovative Medicine, Bristol Myers Squibb, Regeneron, AbbVie and Roche, Janssen Pharma

The Key Multiple Myeloma Companies in the market include – Johnson & Johnson Innovative Medicine, Bristol Myers Squibb, Regeneron, AbbVie and Roche, Janssen Pharmaceutical, Regeneron Pharmaceuticals, Cartesian Therapeutics, Alliance Foundation Trials, LLC., US Oncology Research, Cartesian Therapeutics, GlaxoSmithKline, Targovax ASA, Janssen Research & Development, AstraZeneca, Celgene, Bristol-Myers Squibb, Pfizer, Ascentage Pharma Group Inc., TeneoOne Inc., Novartis, and others.

 

The Multiple Myeloma market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Multiple Myeloma pipeline products will significantly revolutionize the Multiple Myeloma market dynamics.

 

DelveInsight’s “Multiple Myeloma Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Multiple Myeloma, historical and forecasted epidemiology as well as the Multiple Myeloma market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Multiple Myeloma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Multiple Myeloma Market Forecast

 

Some of the key facts of the Multiple Myeloma Market Report:

  • The Multiple Myeloma market size was valued approximately USD ~21 billion in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

  • In March 2025, The HealthTree Foundation has launched a cutting-edge AI-powered Personalized Clinical Trial Finder designed to assist multiple myeloma (MM) patients in locating suitable clinical trials. Now part of the HealthTree Cure Hub Registry, this advanced tool leverages artificial intelligence to analyze individual medical histories, making the trial matching process more precise and efficient.

  • In January 2025, Sanofi, a pharmaceutical company based in France, has announced positive results from its Phase III IRAKLIA trial evaluating Sarclisa (isatuximab) as a treatment option for multiple myeloma (MM). The study enrolled 531 adult MM patients who had previously undergone at least one line of therapy, including treatment with lenalidomide and a proteasome inhibitor, across 252 international sites. The trial achieved its co-primary endpoints with Sarclisa—administered subcutaneously using an on-body delivery system (OBDS)—in combination with pomalidomide and dexamethasone (Pd).

  • In September 2024, Johnson & Johnson has shared results from its Phase III CARTITUDE-4 clinical trial, revealing that its cell therapy, CARVYKTI (ciltacabtagene autoleucel), led to a significant improvement in overall survival for patients with multiple myeloma. The study included patients who had received at least one prior line of treatment, including a proteasome inhibitor (PI). In a randomized trial design, CARVYKTI was evaluated against standard treatment regimens such as pomalidomide, bortezomib, and dexamethasone (PVd), or daratumumab, pomalidomide, and dexamethasone (DPd).

  • In August 2024, Opna Bio, a Swiss biopharmaceutical firm, has initiated dosing in its Phase I clinical trial of OPN-6602, an EP300/CBP bromodomain inhibitor being developed for the treatment of multiple myeloma. The study aims to recruit up to 130 patients with relapsed or refractory multiple myeloma at various sites across the United States. The first dose was administered at The START Center for Cancer Research in Grand Rapids, Michigan.

  • In April 2024, Bristol Myers Squibb (NYSE: BMY) and 2seventy bio, Inc. (Nasdaq: TSVT) announced that the U.S. Food and Drug Administration (FDA) approved Abecma® (idecabtagene vicleucel; ide-cel) on April 4, 2024, for adults with relapsed or refractory multiple myeloma who have received at least two previous lines of therapy. These prior treatments must include an immunomodulatory agent (IMiD), a proteasome inhibitor (PI), and an anti-CD38 monoclonal antibody. This expanded approval, supported by the KarMMa-3 trial, enables earlier use of Abecma in patients who have been exposed to all three therapy classes (triple-class exposed). Abecma is delivered as a single infusion, with a newly recommended dose range of 300 to 510 x 10⁶ CAR-positive T cells.

  • In 2023, the total market size for multiple myeloma in the US was approximately USD 14.3 billion, with expectations of growth by 2034.

  • In March 2024, Johnson & Johnson announced that the US Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) has recommended CARVYKTI for treating adult patients with Relapsed/Refractory Multiple Myeloma (RRMM) who have undergone at least one prior therapy, including a proteasome inhibitor and an IMiD, and are refractory to lenalidomide.

  • In the 4L+ setting, approved CAR-T therapies (ABECMA and CARVYKTI) were projected to generate approximately USD 828 million in the US in 2023, with this figure expected to increase as new CAR-T therapies gain approval throughout the forecast period.

  • In 2023, the total number of incident cases of multiple myeloma in the 7MM was approximately 75,000, and this figure is expected to grow throughout the forecast period.

  • In the 7MM, the United States recorded the highest number of incident cases of multiple myeloma, followed by the EU4 nations and the UK.

  • In 2023, Germany had the highest number of incident cases of multiple myeloma among the EU4 countries and the UK, while Spain had the lowest.

  • Multiple myeloma is more prevalent in males than in females, with over 50% of cases in the United States being diagnosed in men.

  • Key Multiple Myeloma Companies: Johnson & Johnson Innovative Medicine, Bristol Myers Squibb, Regeneron, AbbVie and Roche, Janssen Pharmaceutical, Regeneron Pharmaceuticals, Cartesian Therapeutics, Alliance Foundation Trials, LLC., US Oncology Research, Cartesian Therapeutics, GlaxoSmithKline, Targovax ASA, Janssen Research & Development, AstraZeneca, Celgene, Bristol-Myers Squibb, Pfizer, Ascentage Pharma Group Inc., TeneoOne Inc., Novartis, and others

  • Key Multiple Myeloma Therapies: CARVYKTI (ciltacabtagene autoleucel), Mezigdomide (CC-92480), Linvoseltamab (REGN5458), Venetoclax, ABBV 383, Talquetamab, Linvoseltamab, Descartes 08, Lenalidomide, Selinexor, Descartes-25, Pomalidomide, TG01, Cyclophosphamide, AZD0305, bb2121, EOS884448, Elranatamab, APG-2575, TNB-383B, PHE885, and others

  • The Multiple Myeloma epidemiology based on gender analyzed that males are affected more in case of Multiple Myeloma as compared to females.

  • The Multiple Myeloma market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Multiple Myeloma pipeline products will significantly revolutionize the Multiple Myeloma market dynamics.

 

Multiple Myeloma Overview

Multiple myeloma is a type of cancer that affects plasma cells, which are a type of white blood cell found in the bone marrow. In multiple myeloma, abnormal plasma cells multiply uncontrollably and produce an excess of abnormal antibodies, which can cause damage to the bones and other organs. Common symptoms include bone pain, weakness, fatigue, frequent infections, and anemia.

 

Get a Free sample for the Multiple Myeloma Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/multiple-myeloma-market

 

Multiple Myeloma Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Multiple Myeloma Epidemiology Segmentation:

The Multiple Myeloma market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Multiple Myeloma

  • Prevalent Cases of Multiple Myeloma by severity

  • Gender-specific Prevalence of Multiple Myeloma

  • Diagnosed Cases of Episodic and Chronic Multiple Myeloma

 

Download the report to understand which factors are driving Multiple Myeloma epidemiology trends @ Multiple Myeloma Epidemiology Forecast

 

Multiple Myeloma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Multiple Myeloma market or expected to get launched during the study period. The analysis covers Multiple Myeloma market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Multiple Myeloma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Multiple Myeloma Therapies and Key Companies

  • CARVYKTI (ciltacabtagene autoleucel): Johnson & Johnson Innovative Medicine

  • Mezigdomide (CC-92480): Bristol Myers Squibb

  • Linvoseltamab (REGN5458): Regeneron

  • Venetoclax: AbbVie and Roche

  • ABBV 383: AbbVie

  • Talquetamab: Janssen Pharmaceutical

  • Linvoseltamab: Regeneron Pharmaceuticals

  • Descartes 08: Cartesian Therapeutics

  • Lenalidomide: Alliance Foundation Trials, LLC.

  • Selinexor: US Oncology Research

  • Descartes-25: Cartesian Therapeutics

  • Pomalidomide: GlaxoSmithKline

  • TG01: Targovax ASA

  • Cyclophosphamide: Janssen Research & Development

  • AZD0305: AstraZeneca

  • bb2121: Celgene

  • EOS884448: Bristol-Myers Squibb

  • Elranatamab: Pfizer

  • APG-2575: Ascentage Pharma Group Inc.

  • TNB-383B: TeneoOne Inc.

  • PHE885: Novartis

 

Discover more about therapies set to grab major Multiple Myeloma market share @ Multiple Myeloma Treatment Landscape

 

Multiple Myeloma Market Strengths

  • Emerging therapies such as CAR-T cell and monoclonal antibodies showing promising results in treating multiple myeloma patients and expected to drive the growth of market. It also amends the treatment landscape in cancer due to its high specificity and minimal side effect profile.

 

Multiple Myeloma Market Opportunities

  • BCMA-targeting therapies are expected to result in noteworthy revenues due to premium pricing and clinical benefit in heavily pretreated patients.

 

Scope of the Multiple Myeloma Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Multiple Myeloma Companies: Johnson & Johnson Innovative Medicine, Bristol Myers Squibb, Regeneron, AbbVie and Roche, Janssen Pharmaceutical, Regeneron Pharmaceuticals, Cartesian Therapeutics, Alliance Foundation Trials, LLC., US Oncology Research, Cartesian Therapeutics, GlaxoSmithKline, Targovax ASA, Janssen Research & Development, AstraZeneca, Celgene, Bristol-Myers Squibb, Pfizer, Ascentage Pharma Group Inc., TeneoOne Inc., Novartis, and others

  • Key Multiple Myeloma Therapies: CARVYKTI (ciltacabtagene autoleucel), Mezigdomide (CC-92480), Linvoseltamab (REGN5458), Venetoclax, ABBV 383, Talquetamab, Linvoseltamab, Descartes 08, Lenalidomide, Selinexor, Descartes-25, Pomalidomide, TG01, Cyclophosphamide, AZD0305, bb2121, EOS884448, Elranatamab, APG-2575, TNB-383B, PHE885, and others

  • Multiple Myeloma Therapeutic Assessment: Multiple Myeloma current marketed and Multiple Myeloma emerging therapies

  • Multiple Myeloma Market Dynamics: Multiple Myeloma market drivers and Multiple Myeloma market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Multiple Myeloma Unmet Needs, KOL’s views, Analyst’s views, Multiple Myeloma Market Access and Reimbursement

 

To know more about Multiple Myeloma companies working in the treatment market, visit @ Multiple Myeloma Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Multiple Myeloma Market Report Introduction

2. Executive Summary for Multiple Myeloma

3. SWOT analysis of Multiple Myeloma

4. Multiple Myeloma Patient Share (%) Overview at a Glance

5. Multiple Myeloma Market Overview at a Glance

6. Multiple Myeloma Disease Background and Overview

7. Multiple Myeloma Epidemiology and Patient Population

8. Country-Specific Patient Population of Multiple Myeloma

9. Multiple Myeloma Current Treatment and Medical Practices

10. Multiple Myeloma Unmet Needs

11. Multiple Myeloma Emerging Therapies

12. Multiple Myeloma Market Outlook

13. Country-Wise Multiple Myeloma Market Analysis (2020–2034)

14. Multiple Myeloma Market Access and Reimbursement of Therapies

15. Multiple Myeloma Market Drivers

16. Multiple Myeloma Market Barriers

17. Multiple Myeloma Appendix

18. Multiple Myeloma Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Multiple Myeloma Market Set to Grow Substantially Through 2034, DelveInsight Projects | Johnson & Johnson Innovative Medicine, Bristol Myers Squibb, Regeneron, AbbVie and Roche, Janssen Pharma

24hrDoc Makes Around-the-Clock Telehealth More Accessible with Services Starting at $39

Houston, TX – May 7, 2025 – 24hrDoc, a leading virtual healthcare provider, is making it easier than ever for individuals to receive fast, affordable, and high-quality care. With consultations starting at just $39, patients can speak with board-certified medical professionals online for a range of common health concerns, receive personalized treatment plans, and have prescriptions sent directly to their preferred local pharmacy, often within hours.

Built on over 20 years of healthcare experience, 24hrDoc has helped thousands of individuals across the US access timely care from the comfort of their homes. The company’s virtual model removes common barriers such as long wait times, high costs, and travel, while delivering trusted medical support at any time of day.

“Our goal is to remove unnecessary barriers to care,” said Ayesha Khan, a representative for 24hrDoc. “Far too often, patients delay treatment due to limited access, high costs, or long wait times. We offer a healthcare solution that combines convenience, affordability, and clinical expertise, putting the control back in the patients’ hands.”

Most consultations through 24hrDoc are completed in 10 minutes or less, reflecting the platform’s commitment to respecting patients’ time. After submitting a short medical questionnaire, users are matched with a licensed provider who reviews the information and creates a personalized treatment plan tailored to the individual’s symptoms and needs. If a prescription is needed, it is sent electronically to the patient’s chosen pharmacy. For select programs, the company also offers home delivery of medications.

24hrDoc is designed for a wide range of illnesses, including non-emergency conditions such as allergies, urinary tract infections, flu, and other issues typically addressed in an urgent care setting. The platform continuously expands and evolves its services to meet the shifting needs of today’s patients. Currently, 24hrDoc provides support for more than two dozen common conditions, offering patients a wide range of virtual care options tailored to everyday health concerns.

The platform has a user-friendly interface, allowing patients to initiate care from any device – no appointments, no waiting rooms, and no insurance required. Services are pay-per-visit, offering flexibility for the uninsured and those seeking a cost-effective alternative to quality care.

As part of its long-term strategy, 24hrDoc is also focused on building a comprehensive digital care network that meets patients where they are. This vision drives the company’s ongoing investment in technology, provider support, and service design, with the goal of creating a seamless healthcare experience that aligns with the realities of today.

With the future of healthcare increasingly digital, 24hrDoc is focused on keeping care simple, fast, and accessible for all – bridging the gap between technology and trusted medical support to meet the needs of today’s patients.

For more information, please visit https://24hrdoc.com.

Media Contact
Company Name: 24hrDoc
Contact Person: Ayesha Khan
Email: Send Email
Phone: (832) 838-4746
Country: United States
Website: https://24hrdoc.com/

U-PASS Launches “Ag Drone Zone” Podcast to Serve Growing Agricultural Drone Community

U-PASS Launches "Ag Drone Zone" Podcast to Serve Growing Agricultural Drone Community

Ag Drone Zone with Britt: U-PASS Launches New Podcast for Ag Drone Pilots

U-PASS, the nation’s largest agricultural drone pilot membership organization, today announced the launch of “Ag Drone Zone,” a dedicated podcast created by agricultural pilots for agricultural pilots. The new series aims to address the evolving challenges and opportunities in the rapidly expanding agricultural drone sector.

Hosted by industry insider Britt, the podcast will deliver practical insights on regulatory compliance, technology advancements, operational best practices, and legislative developments affecting agricultural drone operations nationwide.

“The agricultural drone industry continues to transform at an unprecedented pace,” said Don Wakamatsu, CEO at U-PASS. “With ‘Ag Drone Zone,’ we’re creating a centralized knowledge resource where both experienced operators and newcomers can stay informed on the developments that directly impact their operations.”

Host Britt brings a diverse background to the podcast, having worked behind the scenes with INDYCAR, served as Miss Rodeo Arizona, and participated in the Wrangler Patriot Tour. This varied experience enables her to approach industry topics from unique angles and ask questions that might otherwise go unexplored.

“My goal with ‘Ag Drone Zone’ is to dig deeper than technical specifications and regulatory text,” explained Britt. “We want to uncover the practical implications and real-world applications that help agricultural drone pilots build successful, compliant operations.”

The podcast will cover essential topics including:

  • Latest drone technology assessments and comparisons
  • FAA compliance guidance and audit preparation
  • State-by-state regulatory updates
  • Congressional legislation affecting agricultural drone operations
  • Industry best practices from leading operators
  • Emerging trends and market opportunities

“Ag Drone Zone” is now available on major podcast platforms including Spotify, Apple Podcasts, YouTube, and directly through the U-PASS website. New episodes will be released twice a month.

For more information about U-PASS or to access the podcast, visit https://www.u-pass.org/

About U-PASS

U-PASS is the largest membership organization for agricultural drone pilots in the United States. Run by active agricultural pilots, the organization provides essential resources, training, and advocacy for drone operators serving the agricultural sector. Through its comprehensive approach to supporting the industry, U-PASS helps members navigate the complex regulatory landscape while advancing operational excellence.

Media Contact
Company Name: U-PASS
Contact Person: Michelle Truman
Email: Send Email
City: PHOENIX
State: Arizona
Country: United States
Website: https://www.u-pass.org/

Unmasking the Industry: Jedi K’s Cinematic Rebellion in Professional Wrestling


Photo Courtesy: Chris Sayers @Chrislostinflorida

Orlando, FL – May 7, 2025 – In an industry where storytelling often follows predictable arcs, Jedi K (Jedediah Koszewski) and Audacity Complex Studios are breaking the mold with a groundbreaking cinematic experience: “Mr. Reset and The Society of Turnbuckle & Bone.” This avant-garde series reimagines professional wrestling through the lens of psychological drama, surrealism, and underground conspiracy, fusing wrestling culture with visual experimentation, horror, satire, and live-action anime.

At the heart of the project is Mr. Reset, a masked, enigmatic figure cloaked in power, mystery, and fear. As the ever-changing grand high master of a covert group known as The Society of Turnbuckle & Bone, he operates behind the scenes as the architect of superstardom in professional wrestling. Set in a shadowy universe governed by secret societies, this cinematic venture peels back the glitzy surface of sports entertainment to expose its darker psychological underpinnings.


Photo Courtesy: Chris Sayers @Chrislostinflorida

In Mr. Reset, rising wrestler Vinny Pacifico plays “Power Punch,” a naive fighter with dreams of glory. His initiation into Reset Wrestling becomes a Faustian journey of sacrifice and self-discovery. Willing to gamble his marriage and morality for a shot at fame, he finds himself under the looming influence of “The Career Assassin” Mr. Fish (played by former NXT star Bobby Fish). Meanwhile, fellow wrestler Jamie Stanley rebels against the society’s grip, undergoing a “Thought Escape Mechanism” guided by Ryzin, “The Reverend of The Rejected.” Together, they uncover “The New Apocalypse”, an eerie unification of wrestlers under Mr. Reset’s rule.

The concept draws inspiration from the immersive theater piece Sleep No More, which left Jedi K deeply impacted. Like that show, Mr. Reset invites viewers into a multi-layered narrative, challenging them to rethink the way wrestling is consumed. Gone are the confines of the traditional ring—this series is a portal into the unseen. Through stylized storytelling and visual chaos, Jedi K urges audiences to explore the wrestling industry’s inner shadows: the manipulation, obsession, and the psychological toll of fame.


Photo Courtesy: Chris Sayers @Chrislostinflorida

As a Cleveland native and 25-year veteran of the wrestling and creative arts scene, Jedi K brings a rare depth of experience. His previous work as a producer for promotions like TNA and Absolute Intense Wrestling set the stage for this evolution. With Mr. Reset, he’s teamed up with visual artist Chris Sayers and genre-defying music producer Tommy Tankx, whose work blends electronic metal, entrance themes, and moody soundscapes. The track “One More Wasted Smile” featuring Steve Rauckhorst, perfectly captures the project’s haunting emotional core.

Mr. Reset and the Society of Turnbuckle & Bone is a must watch series. A challenge to the industry’s stagnant narratives. A spotlight on its secret architects. And an invitation to viewers: Stop accepting wrestling as it’s handed to you. Instead, question the forces shaping it. Peel back the mask. See who’s really in control.

At its core, the series proposes a gripping premise: secret societies have long influenced the superstars and structures within professional wrestling. The Society of Turnbuckle & Bone, led by the masked and mysterious Mr. Reset, is the invisible hand shaping careers and destinies from the shadows. With a face of wealth, a tuxedo, and a terrifying legacy, Mr. Reset serves as both gatekeeper and judge, orchestrating the rise and fall of those desperate for fame.

Drawing inspiration from the immersive theater piece Sleep No More, Jedi K has crafted a multi-layered narrative that challenges how wrestling is consumed. This isn’t just a wrestling show—it’s a surreal plunge into obsession, manipulation, and the psychological toll of fame. Gone are the ring ropes; in their place, visual chaos and layered meaning.

As a Cleveland native and 25-year veteran of wrestling and creative production, Jedi K’s experience underpins this ambitious vision. His collaborators, visual artist Chris Sayers and genre-blurring music producer Tommy Tankx, infuse the project with distinct artistic force. Tankx, known for work with Static X and wrestling stars like Adam Scherr and EC3, delivers a haunting sonic backdrop. The standout track “One More Wasted Smile,” featuring Steve Rauckhorst, resonates with the emotional weight of the story.

Mr. Reset and the Society of Turnbuckle & Bone is a spotlight on the industry’s hidden hands. And an invitation: question the spectacle, challenge the power behind the curtain, and dare to see what lies beneath the mask.

Learn more at www.AudacityComplex.com or www.TurnbuckleAndBone.com.

Media Contact
Company Name: Audacity Complex Studios
Contact Person: Jedi Koszewski
Email: Send Email
Phone: (216)313-7545
Country: United States
Website: http://www.AudacityComplex.com

Rayobyte Unveils AI-Powered Web Scraping API: Turning Public Web Data Into Business Gold

Lincoln, NE – May 7, 2025 – Rayobyte, a leading innovator in ethical and large-scale data collection, is proud to announce the official launch of its Web Scraping API, a next-generation tool designed to empower businesses with the ability to collect public web data at scale and transform it into meaningful, actionable insights using advanced AI and machine learning technologies.

Rayobyte’s Web Scraping API

Built on the philosophy that data is the new gold, Rayobyte’s Web Scraping API gives companies the power to mine, refine, and capitalize on publicly available information across websites and social media platforms, in real time and without the usual complexity of traditional scraping tools.

“We’re not just helping businesses extract data, we’re helping them understand it,” says Neil Emeigh, Founder and CEO of Rayobyte. “Our Web Scraping API isn’t just fast and scalable. It’s smart. By integrating AI and machine learning directly into the scraping process, we make it easier than ever to transform massive volumes of raw data into clear insights that drive smart decisions.”

Turning Raw Data into Refined Strategy

The new API delivers a streamlined pipeline from data extraction to data intelligence, starting with smart scraping capabilities that navigate complex site structures and bypass anti-bot systems, ethically and reliably. Once collected, AI-driven preprocessing tools clean and organize the data to remove noise, outliers, and inconsistencies, making it analysis-ready from the start.

“Think of it like mining for gold,” explains Emeigh. “Web scraping pulls in raw material – tons of data from across the internet. But that material only becomes valuable when it’s refined. Our system polishes it through preprocessing, analysis, and predictive modeling.”

From Insight to Prediction

The Web Scraping API goes beyond basic data collection by laying the groundwork for sophisticated predictive modeling. Using historical and real-time data, businesses can identify trends, forecast outcomes, and tailor strategies in areas like marketing, product development, customer engagement, and more.

With the addition of AI, the API automatically adapts to changing site structures, selects relevant content, and supports large-scale aggregation, unlocking insights that were previously impossible to access at scale.

Built for Interdisciplinary Teams

Rayobyte’s Web Scraping API is also designed with interdisciplinary collaboration in mind. Whether it’s marketers tracking brand sentiment, analysts forecasting sales, or data scientists building AI models, the tool provides clean, comprehensive datasets that support every stage of the decision-making process.

“Each discipline brings a unique perspective and skill set to the table,” says Emeigh. “Web scraping plays a foundational role in this collaboration by efficiently gathering large volumes of data from across the internet, allowing teams to focus on analysis and strategic decision-making.”

Key Features of the Rayobyte Web Scraping API:

  • AI & ML Integration for smart extraction and preprocessing

  • Scalable Infrastructure for high-volume public data collection

  • Customizable Output Formats for seamless analysis and integration

  • End-to-End Automation, from scraping to preprocessing to insight generation

For more information about the Rayobyte Web Scraping API, visit: https://rayobyte.com/products/web-scraper-api/.

About Rayobyte

Rayobyte is a trusted leader in proxy solutions and data infrastructure, empowering organizations to access, collect, and analyze public web data at scale. With a focus on ethics, performance, and transparency, Rayobyte provides the tools businesses need to turn data into decisions—and decisions into growth.

Socials: X, YouTube, LinkedIn

Media Contact
Company Name: Rayobyte
Contact Person: Michael Woo
Email: Send Email
Phone: +1 800-484-0229
Country: United States
Website: https://rayobyte.com/

Mastering Business Storytelling: The Must-Read Leadership Book for Global Executives Launches June 2025

“A promotional graphic for the book Mastering Business Storytelling by Taty Fittipaldi. The image features the hardcover book standing upright on a white surface, set against a light textured wall. The book cover has a playful illustration of a stick figure (Mr. Lines) riding a rocket above the Earth, symbolizing global leadership. To the right of the book is a black Amazon badge that says “Available at Amazon” above a prominent blue QR code.”
New book by global leadership expert and executive coach Taty Fittipaldi reveals how global leaders can master storytelling as a strategic tool to inspire, influence, and drive success.

Denville, NJ – May 7, 2025 – Coaching Expatriates Publishing is proud to announce the upcoming release of Mastering Business Storytelling: How Global Executives Can Craft and Tell Impactful Stories That Inspire, Influence, and Drive Success in Business By Using Frameworks They Already Know, written by renowned executive coach and leadership expert Taty Fittipaldi. The book is set to launch on June 24, 2025, with pre-orders available on Amazon Kindle.

With business storytelling emerging as a critical leadership skill, this book provides global executives with a practical, neuroscience-backed approach to crafting powerful stories that captivate audiences, enhance decision-making, and inspire action.

Why Business Storytelling Matters for Global Executives

Mastering Business Storytelling tackles a critical challenge: many executives struggle to make their messages stick. Despite data-driven presentations and well-crafted strategies, leaders often fail to engage and persuade effectively.

This book provides a step-by-step storytelling framework tailored for global executives, showing them how to:

• Transform dry business messages into compelling narratives that engage and inspire.

• Reframe existing narratives strategically to influence stakeholders and teams.

• Apply storytelling across leadership scenarios—from boardrooms to client meetings.

• Understand the neuroscience behind storytelling and how it impacts decision-making.

• Build a personal catalog of impactful stories for quick use in high-stakes moments.

“With the right story, any leader can achieve anything,” says Fittipaldi. “It’s not about changing reality—it’s about strategically reframing narratives to align with what you want to achieve. When you tell the right story at the right time, you become unstoppable.”

A Book That Stands Out in the Leadership Space

Unlike other storytelling books that focus solely on speeches or presentations, Mastering Business Storytelling integrates storytelling into everyday leadership communication—helping leaders transform ordinary interactions into moments of influence.

Fittipaldi’s approach is grounded in:

  • Real-world case studies showcasing storytelling’s impact on leadership.
  • Easy-to-use frameworks that executives can implement immediately.
  • A visually engaging, light, and practical reading experience.

A Global Leadership Expert’s Mission

Drawing from over two decades leading Fortune 500 teams and coaching global executives, Taty Fittipaldi saw firsthand how leaders struggled to connect, inspire, and influence through communication. Recognizing that storytelling was the missing leadership superpower, she wrote this book to make strategic storytelling accessible, actionable, and indispensable for every executive.

“Leadership isn’t just about making decisions—it’s about making an impact,” says Fittipaldi. “And the right story, told the right way, has the power to do exactly that.”

Pre-Order & Media Inquiries

Mastering Business Storytelling is available for pre-order on Amazon Kindle from March until June 24, 2025. For media inquiries, interviews, or speaking engagements, please contact press@coachingexpatriates.com.

About the Author

Taty Fittipaldi is an executive coach, leadership trainer, and author of Mastering Business Storytelling. With over 20 years of experience leading multi-billion-dollar business initiatives, she specializes in helping global executives leverage storytelling to enhance leadership impact and influence. As the founder of Coaching Expatriates®, she empowers leaders to turn HR initiatives into success stories and drive organizational transformation.

Watch the Book’s Trailer

Video Link: https://www.youtube.com/embed/d_7s692Bs5M

Media Contact
Company Name: Coaching Expatriates LLC
Contact Person: Taty Fittipaldi
Email: Send Email
Phone: 5512274499
Address:276 East Main Street Suite 10 #407
City: Denville
State: NJ
Country: United States
Website: https://www.coachingexpatriates.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Mastering Business Storytelling: The Must-Read Leadership Book for Global Executives Launches June 2025

Morelli Law Firm Pursues Wrongful Death Case in Manhattan Garage Collapse, Citing Engineering Negligence and Widespread Building Safety Failures

In the wake of a city investigation deeming the collapse “reckless,” Morelli Law Firm demands accountability for fatal failures in safety and oversight

New York, New York – Morelli Law Firm is representing the family of Willis Moore, the long-serving garage manager tragically killed in the 2023 parking garage collapse in Lower Manhattan. Moore, who worked at the garage for more than 20 years, lost his life when the building suddenly gave way—an incident that injured several others and caused widespread property damage.

A new report released by the New York City Department of Buildings (DOB) highlights a disturbing series of failures that led to the collapse. The findings, described by the DOB as “reckless,” pinpoint poor maintenance, ignored structural issues, and unsafe repair work as the direct causes of the building’s failure. As reported by ABC7 New York and detailed in a New York Times investigation, the garage’s attempts to shore up the structure not only failed to stabilize it but may have hastened its collapse.

“The DOB report confirms what we’ve alleged from the beginning—this was not an accident; it was a preventable tragedy caused by years of neglect,” said Benedict Morelli, founding partner of Morelli Law Firm. “This building was a ticking time bomb, and no one acted to defuse it.”

According to the DOB, the collapse was the result of corroded support beams and columns that had not been properly inspected or repaired. In fact, the garage’s attempts to reinforce the structure, including pouring new concrete, only added stress and made the building less stable. Investigators also found that multiple cars were being stored on elevated lifts beyond the structure’s capacity, a practice that exacerbated the structural strain.

“This garage’s operators ignored basic safety protocols,” added Morelli. “They failed to follow engineering best practices, failed to address known deterioration, and failed to ensure the safety of the very people working in and around the building every day.”

The report’s release has sparked renewed calls for better oversight of aging infrastructure throughout New York City. In the wake of the collapse, city inspectors increased the pace of building checks—but for Morelli, that response came far too late.

“It shouldn’t take someone dying to prompt action,” said Morelli. “There are hundreds of aging structures across the city, and unless serious reforms are made, we will see tragedies like this again.”

The case, filed by the Morelli Law Firm, seeks accountability for the wrongful death of Willis Moore and justice for a family who lost a loved one due to what the city has now confirmed was preventable negligence.

About Morelli Law Firm

Morelli Law Firm, based in New York City, is a premier civil litigation firm with over 40 years of combined experience. Renowned for its precedent-setting verdicts and settlements, the firm has helped secure billions in compensation for victims of negligence and misconduct.

For more information about Morelli Law Firm, visit their site HERE.

Media Contact
Company Name: Morelli Law Firm
Contact Person: Caleb Harper
Email: Send Email
Country: United States
Website: https://www.morellilaw.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Morelli Law Firm Pursues Wrongful Death Case in Manhattan Garage Collapse, Citing Engineering Negligence and Widespread Building Safety Failures

Hereditary Spastic Paraplegia Market Poised for Significant Growth with the Emergence of Gene Therapies | DelveInsight

“Hereditary Spastic Paraplegia Market Report”
The hereditary spastic paraplegias treatment market is poised for significant expansion over the coming years, driven by advances in gene therapy, improved diagnostic capabilities, and growing research into targeted treatments for this rare neurological disorder.

DelveInsight’s “Hereditary Spastic Paraplegias Market Insights, Epidemiology, and Market Forecast-2032” report provides an in-depth understanding of the hereditary spastic paraplegias market size, including historical and forecasted epidemiology, current treatment approaches, and emerging therapies across the 7MM. The report details treatment practices, emerging drugs, market share of individual therapies, and forecasted market size from 2019 to 2032, offering valuable insights for stakeholders and decision-makers in the neurological disorders therapeutic landscape.

Hereditary spastic paraplegias represents a clinically and genetically heterogeneous group of neurodegenerative disorders characterized by progressive spasticity and weakness of the lower limbs due to axonal degeneration in the corticospinal tracts.

The hereditary spastic paraplegias market is expected to expand steadily across 7MM over the coming decade, with total revenues growing at a decent CAGR by 2032. The US has the the largest share of hereditary spastic paraplegias treatment market among 7MM, mainly due to the robust healthcare funding, widespread adoption of advanced neuroimaging and genetic testing platforms, and strong patient-advocacy efforts are accelerating diagnosis rates and driving uptake of both symptomatic and emerging disease-modifying therapies.

Explore the driving factors behind the hereditary spastic paraplegias treatment market @ Hereditary Spastic Paraplegias Market Trends.

Furthermore, rising disease awareness, improved diagnostic reporting, and an acute unmet need for targeted therapies are prompting pharmaceutical and biotech companies to invest heavily in hereditary spastic paraplegias research and development.

The epidemiological data presented in the report indicate key trends in incidence, demographics, and the hereditary spastic paraplegias patient pool. Hereditary spastic paraplegias affect roughly 0.1 to 9.6 individuals per 100K globally, with the US reporting approximately 3 cases per 100K. Japan’s prevalence is lower at around 0.2 per 100K. Furthermore, improved genetic screening and neuroimaging have led to increased diagnosis rates across the 7MM, revealing more than 80 causative genes and suggesting that many cases were previously underrecognized.

For hereditary spastic paraplegias patient pool forecasts and trends, visit @ Hereditary Spastic Paraplegias Epidemiological Analysis.

The current hereditary spastic paraplegias therapeutic landscape is limited to symptomatic management, as no disease-modifying treatments are currently available. Treatment approaches focus primarily on reducing muscle spasticity, improving strength and gait, and addressing urinary symptoms. The therapeutic arsenal includes physical therapy, oral antispastic medications, such as Baclofen, Progabide, and Dalfampridine, botulinum toxin injections for focal spasticity, and surgical interventions such as intrathecal baclofen pump implantation in severe cases. However, these approaches fail to address the underlying neurodegeneration, highlighting the critical hereditary spastic paraplegias unmet need.

The hereditary spastic paraplegias pipeline has witnessed encouraging developments in recent years, with multiple therapeutic approaches under investigation. Gene therapy has emerged as a promising avenue, particularly for SPG4, the most prevalent form of autosomal dominant HSP. Collaborative research between UMass Chan Medical School and Drexel University, supported by the Cure SPG4 Foundation, is advancing AAV9-based gene therapy for SPG4, with positive initial results observed in preclinical models.

Strategic collaborations and licensing deals between academic institutions and industry players further strengthen the development landscape, suggesting a gradually shifting therapeutic paradigm from purely symptomatic management toward disease modification and personalized medicine in hereditary spastic paraplegias.

Recent advances in the hereditary spastic paraplegia therapeutic landscape have been driven primarily by precision gene-replacement strategies targeting AP-4 complex defects. In April 2025, the FDA granted IND clearance along with orphan drug and rare pediatric disease designations to BlackfinBio’s AAV-based BFB-101 for SPG47, clearing the way for a Phase 1/2 open-label intrace­rebroventricular study at Boston Children’s Hospital in up to five pediatric patients.

Discover recent advancements in the hereditary spastic paraplegias treatment landscape @ Hereditary Spastic Paraplegias Recent Developments.

Despite these advances, significant challenges remain in the hereditary spastic paraplegia market, including diagnostic delays, genetic heterogeneity, and the complexity of developing therapies for rare disease populations. These factors have traditionally limited pharmaceutical interest in the hereditary spastic paraplegia therapeutic space, though the growing focus on rare diseases and advances in precision medicine are gradually shifting this landscape.

Looking ahead, the hereditary spastic paraplegia market is expected to witness continued growth driven by increasing disease awareness, improved genetic testing capabilities, and the potential approval of novel disease-modifying therapies. The integration of biomarkers for disease progression and treatment response will likely play a critical role in clinical trial design and therapeutic development. As research continues to uncover the molecular mechanisms underlying different hereditary spastic paraplegia subtypes, targeted approaches addressing specific pathophysiological pathways are anticipated to reshape the treatment paradigm and improve outcomes for patients with this progressive neurological disorder.

Table of Contents

1. Key Insights

2. Executive Summary of Hereditary Spastic Paraplegias

3. Competitive Intelligence Analysis for Hereditary Spastic Paraplegias

4. Hereditary Spastic Paraplegias: Market Overview at a Glance

5. Hereditary Spastic Paraplegias: Disease Background and Overview

6. Patient Journey

7. Hereditary Spastic Paraplegias Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Hereditary Spastic Paraplegias Unmet Needs

10. Key Endpoints of Hereditary Spastic Paraplegias Treatment

11. Hereditary Spastic Paraplegias Marketed Products

12. Hereditary Spastic Paraplegias Emerging Therapies

13. Hereditary Spastic Paraplegias: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Hereditary Spastic Paraplegias

17. KOL Views

18. Hereditary Spastic Paraplegias Market Drivers

19. Hereditary Spastic Paraplegias Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hereditary Spastic Paraplegia Market Poised for Significant Growth with the Emergence of Gene Therapies | DelveInsight